• Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study

    4 days ago - By San Diego Biotechnology

    Positive Data Updates Presented at the Society of Neuro-Oncology Annual Meeting in Newly-Diagnosed, Recurrent, and First-Line GBM- In the Newly-Diagnosed Treatment Setting, Promising Median Progression-Free Survival of 10.0 months with VAL-083 Co......
    Read more ...